Pharmaceutical

Expert analysis: the latest in HIV research and clinica...

A new report from Novotech delves into the multifaceted landscape of HIV, focusi...

Diakonos’ brain tumour vaccine wins FDA’s orphan drug d...

The immuno-oncology company has also completed enrolment in a Phase I trial inve...

UK MHRA introduces new procedure for medicine approvals

The UK MHRA has introduced the International Recognition procedure (IRP), a new ...

Oragenics acquires neurological assets from Odyssey Health

Oragenics has concluded the announced acquisition of assets focusing on neurolog...

STAT+: Pharmacies fear New Year’s financial squeeze fro...

Under a new policy, there will be a period when pharmacies are being billed PBM ...

STAT+: 2024 could be a turning point for the regulation...

In health care, predictive AI models may have to explain how their systems were ...

Opinion: Today’s at-home microbiome testing industry is...

A gastroenterologist explains why patients who are investing in at-home microbio...

STAT+: Consumer health advocate Sid Wolfe was a thorn i...

Passionate and meticulous, Sid Wolfe, who died Sunday, was the consummate public...

STAT+: A single drug and multiple study failures leave ...

It took Anavex Life Sciences seven months to finally acknowledge the failure of ...

STAT+: LabCentral, a crucial Boston incubator for drug ...

Biotech incubator LabCentral has expanded rapidly amid fluctuating vacancy rates...

UnitedHealth’s rehab restrictions, Texas medical school...

The latest edition of STAT's Health Care Inc. newsletter touches on UnitedHealth...

An ugly fight over care for the poor in Texas

Read this week's edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about...

STAT+: Pharmalittle: Drugmakers raise prices, pharmacie...

Drugmakers plan to raise prices in the United States on more than 500 drugs in e...

STAT+: Here’s who’s profiting the most in health care

Ahead of the dealmaking & hobnobbing of #JPM2024, STAT took a look at which #hea...

STAT+: The biotech scorecard for the first quarter: 17 ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech eve...

STAT+: It was a turbulent year for the business of heal...

In 2023, selling tech-enabled health care services was slow and hard, even for s...